$IMNN

Eylward Susan sold $4K of IMNN

Eylward Susan (General Counsel and Corp Sec) sold 2,150 shares of Imunon, Inc. (IMNN) at $1.78 on 2026-07-20.

Original reporting
SEC EDGAR · Eylward Susan
Published Jul 21, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 12:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IMNN
Neutral
medium confidence
Mentioned
$IMNN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IMNNNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details by the issuer’s general counsel, including share count, price, and post-transaction holdings.

02

Market read

Traders may note insider selling, but the disclosed transaction value is small and lacks accompanying fundamental catalysts.

03

What to watch

The absence of a 10b5-1 plan could raise scrutiny, but the filing provides no context for motive or whether other insiders are selling/buying around the same time.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-21 after-hours; sale dated 2026-07-20

Background

The article is an SEC Form 4 insider transaction disclosure for Imunon, Inc. (IMNN).

Company-level read

Ticker impact

$IMNNNeutralMedium confidence
Context

SEC Form 4 shows IMUNON general counsel sold 2,150 shares on 2026-07-20 at $1.7816, totaling $3,830.44.

Expected impact

Likely limited near-term impact; treat as low-signal unless repeated or paired with other negative disclosures.

Evidence & confidence

The filing is primary-source but the transaction size is small and does not include new company fundamentals, guidance, or regulatory/operational events.

Market effects

No clear sector read-through from a small insider sale filing.

None.

None.

Counterpoint

Insider sales can be for diversification or personal liquidity needs and may not reflect negative expectations, especially for small dollar amounts.

Key entities

  • Imunon, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Eylward Susan

    General Counsel and Corp Sec who sold 2,150 shares.

Related articles

$IMNNMed

EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study - Im

Imunon Inc. (NASDAQ:IMNN) updated its pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer. The company said site activation and enrollment are ahead of forecasts, with full enrollment expected by Q2 2029. It reported no cytokine release syndrome or serious immune-related adverse events and noted two interim analyses that could support an early BLA. Shares rose 1.95% to $1.57 premarket.

$IMNNMed

Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer

IMUNON (Nasdaq: IMNN) provided an update on its pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer. The company said enrollment is ahead of plan, with a study rate of about 0.5 patients per site per month versus 0.3 planned, and it now expects completion in Q2 2029. It reported no cytokine release syndrome and comparable safety versus control.

$IMNNMedAI 9/10

Imunon Secures $10 Million Funding Package to Advance Phase 3 Ovarian Cancer Study (IMNN)

Imunon Inc. (NASDAQ:IMNN) said it secured a $10 million financing package to advance its Phase 3 OVATION 3 ovarian cancer trial of IMNN-001. The company will receive $2.5 million via 250 non-redeemable, non-convertible preferred shares and about $7.72 million through two secured promissory notes at 8% and 5% interest, maturing in 18 months. Imunon cited updated Phase 2 survival data.